Figure 5. Neoadjuvant therapy alters the expression levels of immunologically relevant proteins in stroma-rich regions.

Expression levels of the indicated proteins. Each dot represents a single region of interest. Individual regions of interest were derived from each patient tumor from a total of n = 6 patient tumors. (A) Signaling pathways. Expression level of signal transduction molecules and cell-cycle–related proteins within stroma-rich regions. (B) Immune checkpoint/activating molecules. Expression level of T cell checkpoint molecules, effector molecules, and other proteins that indicate immune cell phenotype within stroma-rich regions. (C) Pan-immune cell markers. Expression level of proteins that indicate immune cell type within stroma-rich regions. *FDR < 0.05 by 1-way ANOVA followed by post test in comparison to surgery-alone patients.